none

A BOOSTER SHOT FOR NATIONAL ECONOMY

10-08-2017
by 
in 

A first-of-its-kind ‘fill-and-finish’ injectable medicines factory will set up shop in South Australia’s Tonsley innovation hub, after securing crucial set-up funds in an investment round.

InDaily revealed last year that biopharmaceutical company GEN1 hoped to create up to 200 new jobs and inject (no pun intended) around $650 million into the state economy over a decade with the establishment of its new operation – which would formulate base compounds into medicines to fill syringes, vials and cartridges as ready-to-use injectables – pending the establishment of a suitable site and international investment.

Both these caveats have now been met, after a funding round – with expected closing next month – raised $8 million through Australian private equity investors, local banks and the South Australian Government’s Health Industries Fund.

GEN1 Chief Financial Officer Kishen Vijayadass said the initial investment round “will support the company’s delivery of a factory in Adelaide that will benefit all Australians”.

“Adelaide has a vibrant, fast-growing life sciences community and the South Australian Government, through Health Industries SA, was very responsive to GEN1 and provided invaluable support,” he said.

The company says its planned 15,000sq m factory will be the first of its kind and scale in Australia, which currently imports injectable medicines for chronic conditions such as cancer, hypertension and diabetes.

However, the national market for injectable medication exceeds $10 billion annually and is growing by 15-20 per cent a year, according to IMS Health.

Health Industries SA CEO Marco Baccanti said GEN1 would be a boon for the state’s health system, with “the potential to save SA up to $70m a year in medication spending”.

“GEN1 will be in a great position to provide high-quality cost-effective products, and it will be doing so locally, right here in Adelaide,” he said.

In a company prospectus issued in May, GEN1 noted Australia was in the top 10 of the highest per capita healthcare spending countries in the world – and the highest in Asia.

“GEN1 is an early entrant to an untapped market, with a business model not in line with the multinationals’ strategy, and out of reach of most local manufacturers,” it said.

“GEN1 offer potential partners a low risk, low cost, quick entry to a high growth industry, with early stage cash flow, relatively fast [return on investment] and a sustainable business growth.”

Related news & editorials

  1. 28.05.2018
    28.05.2018
    by      In
    Western Australia has a new naval shipbuilder in the shape of the Australian Maritime Shipbuilding & Export Group, a joint venture between Luerssen and Civmec set up to build ten Offshore Patrol Vessels.
    In November 2017, Luerssen was chosen as the prime contractor to supply 12 OPVs to the Navy... Read More
  2. 24.05.2018
    24.05.2018
    by      In
    Rio Tinto has announced that Australia’s Office of the National Rail Safety Regulator has approved the autonomous operation of trains at its iron ore businesses in WA.
    After several years of regulatory hurdles, delays, and slowly increasing coverage of its automated haulage network of freight... Read More
  3. 24.05.2018
    24.05.2018
    by      In
    A new reactive battery system has been switched on, stabilising the power grid of a coastal town with wildly variable energy demands.
    The autonomous system is located in the fishing village of Cape Jervis, and is part of a $3.65 million power stabilisation trial that could lead to town batteries... Read More
  4. 24.05.2018
    24.05.2018
    by      In
    The world of workplace health and safety descended on the Melbourne Convention & Exhibition Centre yesterday for the first day of the all-new Workplace Health & Safety Show. And it did so in big numbers, with the opening day attendance estimated in excess of 1200.
    It helped that the show is... Read More